Illumina, Inc. $ILMN Stock Sold by D.A. Davidson & CO.

Key Points

• D.A. Davidson & Co. reduced its Illumina stake by 27.9% in the third quarter, selling 6,419 shares and retaining 16,601 shares valued at approximately $4.54 million. Institutional investors still own 89.42% of the company.
• Illumina exceeded quarterly earnings expectations, reporting EPS of $1.62 versus the $1.36 consensus and revenue of $1.17 billion. However, concerns over China exposure, tariffs, softer research-market demand and business mix continue to weigh on investor sentiment.
• Analyst views remain mixed, with nine Buy, seven Hold and three Sell ratings; the consensus rating is Hold with an average price target of $238.53. Insider selling was also significant, including a director’s $91.6 million share sale.

D.A. Davidson & CO. decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 27.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,601 shares of the life sciences company's stock after selling 6,419 shares during the period. D.A. Davidson & CO.'s holdings in Illumina were worth $4,543,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Illumina in the second quarter valued at approximately $3,374,423,000. Plato Investment Management Ltd bought a new position in Illumina in the 2nd quarter worth approximately $948,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Illumina in the 2nd quarter worth approximately $30,501,000. Edmond DE Rothschild Holding S.A. acquired a new position in Illumina during the 2nd quarter worth $129,792,000. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new position in Illumina during the 2nd quarter worth $6,711,000. Institutional investors own 89.42% of the company's stock.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of recent research reports. Barclays increased their price objective on Illumina from $160.00 to $200.00 and gave the company an "underweight" rating in a research report on Wednesday, October 7th. Piper Sandler boosted their target price on Illumina from $225.00 to $305.00 and gave the stock an "overweight" rating in a research report on Monday, September 28th. Argus boosted their target price on Illumina from $180.00 to $235.00 and gave the stock a "buy" rating in a research report on Thursday, September 3rd. Stephens lowered Illumina from an "overweight" rating to an "equal weight" rating and set a $275.00 price target on the stock. in a research note on Friday, October 23rd. Finally, UBS Group upgraded Illumina from a "neutral" rating to a "buy" rating and raised their price target for the company from $135.00 to $260.00 in a report on Wednesday, September 9th. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $238.53.

Illumina Stock Down 18.6%

NASDAQ:ILMN opened at $235.99 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 12-month low of $106.12 and a 12-month high of $309.35. The stock's fifty day simple moving average is $249.30 and its 200-day simple moving average is $176.18. The firm has a market capitalization of $35.63 billion, a P/E ratio of 40.62, a P/E/G ratio of 3.34 and a beta of 1.41.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.36 by $0.26. The firm had revenue of $1.17 billion for the quarter, compared to analysts' expectations of $1.15 billion. Illumina had a return on equity of 29.41% and a net margin of 19.72%. The company's revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the business earned $1.34 earnings per share. Equities research analysts expect that Illumina, Inc. will post 5.43 earnings per share for the current year.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

Insider Activity

In related news, Director Keith Meister sold 457,858 shares of the company's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares in the company, valued at $474,776,069.40. This represents a 16.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have sold 2,061,235 shares of company stock valued at $436,356,102. 2.90% of the stock is owned by insiders.

Illumina Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.